Bekele Yonas, Mengistu Yohannes, de Wit Tobias Rinke, Wolday Dawit
Addis Ababa University, Addis Ababa, Ethiopia.
Ethiop Med J. 2011 Jul;49(3):187-97.
Variability in CD4 T-cell counts has been described for both healthy and HIV-infected persons. It may influence decisions with respect to initiation and monitoring of antiretroviral treatment.
to measure the effect of timing of blood sampling for blood cell count measurement.
The study population consisted of 71 Ethiopian patients in an observational cohort, either being monitored prior to HAART (n = 40) or receiving HAART (n = 31) at an ART Clinic in Addis Ababa.
The median CD4 count demonstrated significantly increasing trends from the morning (8 am) to the afternoon (4 pm), both for patients on HAART (increase of 137 CD4 cell/microl; p = 0.003) and for patients initiating HAART (increase of 56 CD4 cells/microl; p = 0.038). This trend was also observed for CD8+ and CD3+ T-lymphocytes, (initiating HAART p = 0.002 and p = 0.001; patients on HAART p = 0.015 and p = 0.004, respectively).
The implications of these findings are for the decision to start HAART or the decision to start prevention of opportunistic infections in Ethiopian patients on HAART.
健康人和感染HIV的人都存在CD4 T细胞计数的变异性。这可能会影响抗逆转录病毒治疗启动和监测方面的决策。
测量血细胞计数测量时采血时间的影响。
研究人群包括71名埃塞俄比亚观察队列患者，其中40名在接受高效抗逆转录病毒治疗（HAART）之前接受监测，31名在亚的斯亚贝巴的一家抗逆转录病毒治疗诊所接受HAART治疗。
无论是接受HAART治疗的患者（CD4细胞计数每微升增加137个；p = 0.003）还是开始接受HAART治疗的患者（CD4细胞计数每微升增加56个；p = 0.038），CD4计数中位数从上午8点到下午4点均呈现显著上升趋势。CD8 +和CD3 + T淋巴细胞也观察到这种趋势（开始接受HAART治疗的患者分别为p = 0.002和p = 0.001；接受HAART治疗的患者分别为p = 0.015和p = 0.004）。
这些发现的意义在于对埃塞俄比亚接受HAART治疗的患者开始HAART治疗或开始预防机会性感染的决策。
